Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

£197m Payments Made Under New UK Pricing Scheme But Access Promises Still To Materialize

Executive Summary

Payments have now been made under the UK’s 2019 pricing and access to branded medicines scheme, but industry will have to wait longer for promises on access to materialize.

You may also be interested in...



Metrics For Measuring UK Pricing Scheme Success: Good Start But More Work Needed

The Pink Sheet’s freedom of information request relating to the 2019 pricing and access to branded medicines scheme has shed light on the metrics being used to gauge whether the scheme is delivering on its promise.

Compulsory License On Table In UK For Orkambi

The UK government will consider all options to improve access to Vertex’s cystic fibrosis treatment, including compulsory licensing.

New UK Price Deal To Save NHS £930m & Speed Up Access To Innovation

The revised PPRS, which is expected to take effect at the beginning of 2019, will implement a 2% cap on the growth in sales of branded medicines to the NHS that should result in substantial savings on medicines spending. It also provides for faster NICE appraisals for non-cancer drugs, and more flexibility in commercial discussions between companies and the health department.

Topics

UsernamePublicRestriction

Register

PS140729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel